Provided by Tiger Trade Technology Pte. Ltd.

Nektar Therapeutics

46.99
-13.5550-22.39%
Post-market: 47.000.0100+0.02%19:59 EDT
Volume:6.27M
Turnover:308.15M
Market Cap:1.60B
PE:-7.26
High:56.69
Open:55.41
Low:46.29
Close:60.55
52wk High:109.00
52wk Low:33.40
Shares:34.14M
Float Shares:28.53M
Volume Ratio:3.19
T/O Rate:21.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.4680
EPS(LYR):-9.7254
ROE:-35.75%
ROA:-12.54%
PB:1.78
PE(LYR):-4.83

Loading ...

Nektar Therapeutics’ Earnings Call Highlights Rezpeg Momentum

TIPRANKS
·
Aug 21

Piper Sandler Remains a Buy on Nektar Therapeutics (NKTR)

TIPRANKS
·
Aug 20

Is Phase III Rezpegaldesleukin And Cash Runway Progress Altering The Investment Case For Nektar Therapeutics (NKTR)?

Simply Wall St.
·
Aug 14

Nektar Therapeutics Falls on Quarterly Revenue Miss

Reuters
·
Aug 14

Nektar Therapeutics Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Earnings Flash (NKTR) Nektar Therapeutics Posts Q2 Loss $1.23 Per Share, vs. FactSet Est of $1.97 Loss

MT Newswires Live
·
Aug 14

Nektar Q2 FY26 Net Loss Narrows to $40.62 Million; Revenue Falls 9.35% to $10.1 Million

Reuters
·
Aug 14

Nektar Q2 2026 Earnings: Phase 3 Spending Rises as Cash and Investments Top $1 Billion

TradingKey
·
Aug 14

Nektar Therapeutics Q2 EPS $(1.23) Beats $(2.00) Estimate, Sales $10.131M Miss $10.425M Estimate

Benzinga Earnings
·
Aug 14

Nektar Therapeutics Q2 EPS USD -1.23

THOMSON REUTERS
·
Aug 14

Earning Preview: Nektar Therapeutics revenue expected to decrease by 3.91%, and institutional views are bullish

Earnings Agent
·
Aug 06

Nektar Therapeutics to Report Q2 Results After U.S. Market Close, Hosts Conference Call

Reuters
·
Jul 29

Is Nektar Therapeutics (NKTR) Undervalued On Its Phase 3 Rezpegaldesleukin Launch?

Simply Wall St.
·
Jul 28

Nektar Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Reuters
·
Jul 25

Nektar Grants 36,000 Inducement Stock Options Priced at $64.84 Per Share

Reuters
·
Jul 25

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Helus Pharma (HELP) and Nektar Therapeutics (NKTR)

TIPRANKS
·
Jul 23

Nektar Therapeutics : Canaccord Genuity Initiates Coverage with Buy Rating; Target Price $153

THOMSON REUTERS
·
Jul 22

Nektar Therapeutics Initiated at Buy by Canaccord Genuity

Dow Jones
·
Jul 22

Cantor Fitzgerald Initiates Nektar Therapeutics at Buy With $153 Price Target

MT Newswires Live
·
Jul 22

Nektar Therapeutics Announces Press Release on Start of Phase 3 Zenith AD Program for Rezpegaldesleukin in Atopic Dermatitis

Reuters
·
Jul 21